Trends in Biotechnology
OpinionSpecial Issue: Computation and ModelingAdvanced Modeling Reconciles Counterintuitive Decisions in Lead Optimization
Section snippets
Counterintuitive Drug Design
We are concerned with molecular targeted therapy, specifically with designing small molecules that bind dysfunctional proteins that need to be blocked for therapeutic purposes 1, 2, 3, 4. Once a target has been validated, drug discovery commences with the identification of a lead. The lead is a compound with nanomolar or submicromolar target affinity and is typically found via high-throughput screening (see Glossary) against a proprietary compound library usually covering vast chemical
Reconciling Counterintuitive Drug Design by Incorporating Three-Body Energy Terms
A targetable backbone amide is known to occur typically in structured regions [7], where it is paired with a backbone carbonyl forming a hydrogen bond. Such water-exposed backbone hydrogen bonds are called dehydrons 4, 11, 12, 13. Due to confinement at subnanometer scales, water vicinal to such dehydrons is frustrated in its hydrogen bonding possibilities as it binds to the backbone carbonyl (Figure 1). This is consistent with the ‘high free-energy content’ (low entropy) of water around
Drug Design Guided by Three-Body Energy Contributions: Reworking Imatinib
To illustrate the overlooked effects of three-body contributions, we need to focus on a LO case that involves exclusively the incorporation of a nonpolar group to the lead scaffold with the express intent of removing water from the vicinity of a specific dehydron in the target protein. Such an example exists: the modification of the cancer drug imatinib by the incorporation of an extra methyl group to enhance the drug affinity and specificity, an optimization decision that resulted in the
Concluding Remarks and Future Perspectives
The end product of the drug discovery process is often far from what one would expect in terms of pairwise matching across the drug–target interface 4, 5, 6, 7, 8, 9. This tells us that LO does not follow a rational path, itself a symptom that the underlying physical principles governing drug–target affinity are not fully understood. LO is mainly guided by screening chemical combinatorial possibilities for lead modification and the net result is seldom intuitively appealing. This black-box
Glossary
- Breakpoint cluster region (BCR)–Abelson murine leukemia (ABL)
- results from a chromosomal translocation whereby the ABL viral oncogene homolog 1 (ABL1) gene from human chromosome 9 is juxtaposed onto the BCR gene from chromosome 22, encoding a hybrid constitutively active signaling protein, the BCR–ABL kinase, that causes cells to divide uncontrollably.
- Chimera
- hybridization and fusion of two or more gene products into a single molecule.
- Chromosomal translocation
- genetic abnormality caused by
References (26)
Guiding lead optimization with GPCR structure modeling and molecular dynamics
Curr. Opin. Pharmacol.
(2016)- et al.
Dehydron: a structurally encoded signal for protein interaction
Biophys. J.
(2003) Lead generation
Thermodynamic proxies to compensate for biases in drug discovery methods
Pharm. Res.
(2016)Physics at the Biomolecular Interface
(2016)An anticancer C-kit kinase inhibitor is re-engineered to make it more active and less cardiotoxic
J. Clin. Invest.
(2007)Understanding kinase selectivity through energetic analysis of binding site waters
ChemMedChem
(2010)Thermodynamic analysis of water molecules at the surface of proteins and applications to binding site prediction and characterization
Proteins
(2012)Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field
J. Am. Chem. Soc.
(2015)Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target
Cancer Res.
(2007)
Differential water thermodynamics determine PI3K-β/δ selectivity for solvent-exposed ligand modifications
J. Chem. Inf. Model.
Epistructural tension promotes protein associations
Phys. Rev. Lett.
Cited by (7)
Making Targeted Therapy Compatible with Checkpoint Immunotherapy
2017, Trends in BiotechnologyCitation Excerpt :While homologous on-target and off-target kinases are structurally similar and therefore difficult to tell apart through molecular recognition, their patterns of packing defects make them distinguishable. Packing defects refer here to water-exposed backbone hydrogen bonds, the so-called ‘dehydrons’ [6]. Interfacial water molecules surrounding dehydrons are constrained and hence easily removable and a payoff for such dehydration is the strengthening and stabilization of the underlying electrostatic interaction [6].
Computing in Biotechnology: Omics and Beyond
2017, Trends in Biotechnology3D-SMGE: a pipeline for scaffold-based molecular generation and evaluation
2023, Briefings in BioinformaticsTopological Dynamics in Metamodel Discovery with Artificial Intelligence: From Biomedical to Cosmological Technologies
2022, Topological Dynamics in Metamodel Discovery with Artificial Intelligence: From Biomedical to Cosmological TechnologiesArtificial Intelligence Platform For Molecular Targeted Therapy: A Translational Science Approach
2021, Artificial Intelligence Platform For Molecular Targeted Therapy: A Translational Science ApproachArtificial Intelligence Teaches Drugs to Target Proteins by Tackling the Induced Folding Problem
2020, Molecular Pharmaceutics